Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearance.
about
Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model VerificationDeveloping a Physiologically-Based Pharmacokinetic Model Knowledgebase in Support of Provisional Model ConstructionA comparative evaluation of models to predict human intestinal metabolism from nonclinical data.Prediction of drug disposition on the basis of its chemical structure.Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance.Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.Mechanistic investigations into the species differences in pinometostat clearance: impact of binding to alpha-1-acid glycoprotein and permeability-limited hepatic uptake.Quantifying and Communicating Uncertainty in Preclinical Human Dose-Prediction.Predictability of plasma concentration-time curves in humans using single-species allometric scaling of chimeric mice with humanized liver.Comparison of predictability for human pharmacokinetics parameters among monkeys, rats, and chimeric mice with humanised liver.A unified strategy in selection of the best allometric scaling methods to predict human clearance based on drug disposition pathway.A Pharmacokinetic Modeling Approach to Predict the Contribution of Active Metabolites to Human Efficacious Dose.Quantitative translational modeling to facilitate preclinical to clinical efficacy & toxicity translation in oncology.
P2860
Q28088352-5CBA53D1-E881-439E-A7B6-20DC02294F21Q28550166-E7E836F1-0082-4FF8-96E8-2B588586293AQ31159063-AFAF1D00-F0FD-4741-8658-0ED287B3E9AFQ38086778-6448FCD3-14F3-4753-A9E6-B89E48072647Q38418951-68B7149B-1CC4-4C9D-8B95-144E1296290FQ38799423-5D3BA743-D6F8-4171-8CDD-2BD7C3B9C463Q38959281-9CED2252-A1EB-4834-A19E-FD792AC031A7Q39782124-37DD2B5E-38D5-4346-8823-706979BDA006Q40606599-5C1DE789-0D57-47E5-A6CB-CCF2145DE38EQ41317951-106FE2DB-02AF-48DA-B7C5-7FF9784EC5D7Q46453943-F0A88F77-FD38-4287-91B2-3BC2316507CDQ46510716-B385813D-72D3-407F-A7F9-310A5447F161Q46751744-F4B71EFF-18EE-4DCB-AE3D-BFF36BBDF43EQ55329667-1FF4F763-662F-4ABA-9B7D-DDB961A33495
P2860
Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearance.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Comprehensive assessment of hu ...... netic data, part 2: clearance.
@ast
Comprehensive assessment of hu ...... netic data, part 2: clearance.
@en
type
label
Comprehensive assessment of hu ...... netic data, part 2: clearance.
@ast
Comprehensive assessment of hu ...... netic data, part 2: clearance.
@en
prefLabel
Comprehensive assessment of hu ...... netic data, part 2: clearance.
@ast
Comprehensive assessment of hu ...... netic data, part 2: clearance.
@en
P2093
P2860
P356
P1476
Comprehensive assessment of hu ...... inetic data, part 2: clearance
@en
P2093
Franco Lombardo
Giuliano Berellini
Ivana Liric Rajlic
Jenny Zhan
Michelle K Dennehy
Mithat Gunduz
R Scott Obach
Shawn P Harriman
P2860
P304
P356
10.1177/0091270012440282
P577
2013-01-24T00:00:00Z